Mesopram

Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. Mesopram inhibits the synthesis of proinflammatory cytokines TNF-α and IFN-γ. Mesopram demonstrates efficacy in ameliorating Dextran sulfate sodium (DSS) (HY-116282C) -induced murine colitis. Mesopram can be used for the study of chronic inflammatory diseases[1][2].

Product Specifications

CAS Number

[189940-24-7]

Product Name Alternative

Daxalipram

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IFNAR; Interleukin Related; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mesopram.html

Purity

98.80

Solubility

10 mM in DMSO

Smiles

O=C1O[C@](C)(C2=CC=C(OC)C(OCCC)=C2)CN1

Molecular Formula

C14H19NO4

Molecular Weight

265.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Blednov YA, et al. Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129.|[2]Loher F, et al. The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther. 2003 May;305 (2) :549-56.